Syndivia – Making a difference in ADC with DAR1
5 (280) · € 21.00 · Auf Lager
Acyl Fluorides: Fast, Efficient, and Versatile Lysine-Based Protein Conjugation via Plug-and-Play Strategy
CPhI Annual Report 2018: ADCs Growth Driven by Lack of In-House Facilities, Oncology and Integrated CDMOs
Full article: Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future
Brandfetch Syndivia Logos & Brand Assets
Combination of IM-Based Approaches to Unravel the Coexistence of Two Conformers on a Therapeutic Multispecific mAb
Reduction-rebridging strategy for the preparation of ADPN-based antibody-drug conjugates. - Abstract - Europe PMC
Syndivia – Making a difference in ADC with DAR1
PDF) Homogeneous antibody-drug conjugates: DAR 2 anti-HER2 obtained by conjugation on isolated light chain followed by mAb assembly
Generation of DAR1 Antibody-Drug Conjugates for Ultrapotent Payloads Using Tailored GlycoConnect Technology
Full article: Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future
Full article: Homogeneous antibody-drug conjugates: DAR 2 anti-HER2 obtained by conjugation on isolated light chain followed by mAb assembly
Antibody–Oligonucleotide Conjugates as Therapeutic, Imaging, and Detection Agents
Sasha Koniev on LinkedIn: Our representation of an antibody-oligonucleotide conjugate (AOC) makes…
Antibody–Oligonucleotide Conjugates as Therapeutic, Imaging, and Detection Agents
